Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 90, Issue 4, 1996, Pages 418-421

  Edstein, M D ^a   Yeo, A E T ^a   Kyle, D E ^b   Looareesuwan, S ^c   Wilairatana, P ^c   Rieckmann, K H ^a  

^a AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Atovaquone; Chemotherapy; Genetic polymorphism; Malaria; Plasmodium falciparum; Proguanil

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; PROGUANIL;

ANTIMALARIAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; GENETIC POLYMORPHISM; HUMAN; MALARIA FALCIPARUM; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PHENOTYPE; PROPHYLAXIS; TREATMENT FAILURE;

PLASMODIUM FALCIPARUM;

EID: 0029815579     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(96)90531-3     Document Type: Article

References (21)

1. Brosen, K., Skjelbo, E. & Flachs, H. (1993). Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. British Journal of Clinical Pharmacology, 36, 105-108.
2. Canfield, C. J., Pudney, M. & Gutteridge, W. E. (1995). Interactions of atovaquone and other antimalarial drugs against Plasmodium falciparum in vitro. Experimental Parasitology, 80, 373-381.
3. Carrington, H. C., Crowther, A. F., Davey, D. G., Levi, A. & Rose, F. I. (1951). A metabolite of paludrine with high antimalarial activity. Nature, 168, 1080.
4. Edstein, M. D., Shanks, G. D., Teja-Isavadharm, P., Rieckmann, K. H. & Webster, H. K. (1994). Oxidative activation of proguanil and dapsone acetylation in Thai soldiers. British Journal of Clinical Pharmacology, 37, 67-70.
5. Fry, M. & Beesley, J. E. (1991). Mitochondria of mammalian Plasmodium spp. Parasitology, 102, 17-26.
6. Gibaldi, M. & Perrier, D. (1982). Pharmacokinetics, 2nd edition. New York: Marcel Dekker.
7. Haile, L. G. & Flaherty, J. F. (1993). Atovaquone: a review. Annals of Pharmacotherapy, 27, 1488-1494.
8. Helsby, N. A., Ward, S. A., Edwards, G., Howells, R. E. & Breckenridge, A. M. (1990). The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. British Journal of Clinical Pharmacology, 30, 593-598.
9. Helsby, N. A., Edwards, G., Breckenridge, A. M. & Ward, S. A. (1993). The multiple dose pharmacokinetics of proguanil. British Journal of Clinical Pharmacology, 35, 653-656.
10. Hudson, A. T., Randall, A. W., Fry, M., Ginger, C. D., Hill, B., Latter, V. S., McHardy, N. & Williams, R. B. (1985). Novel antimalarial hydroxynaphthpquinones with potent broad spectrum anti-protozoal activity. Parasitology, 90, 45-55.
11. Hudson, A. T., Dickins, M., Ginger, C. D., Gutteridge, W. E., Holdich, T., Hutchinson, D. B. A., Pudney, M., Randall, A. W. & Latter, V. S. (1991). 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs in Experimental Clinical Research, 17, 427-435.
12. Lambros, C. & Vanderberg, J. P. (1979). Synchronization of Plasmodium falciparum erythrocytic stages in culture. Journal of Parasitology, 65, 418-420.
13. Looareesuwan, S., Viravan, C., Webster, H. K., Kyle, D. E., Hutchinson, D. B. & Canfield, C. J. (1996). Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. American Journal of Tropical Medicine and Hygiene, 54, 62-66.
14. Rolan, P. E., Mercer, A. J., Weatherley, B. C., Holdich, T., Meire, H., Peck, R. W., Ridout, G. & Posner, J. (1994). Examination of some factors responsible for a food-induced increase in absorption of atovaquone. British Journal of Clinical Pharmacology, 37, 13-20.
15. Setiabudy, R., Kusaka, M., Chiba, K., Darmansjah, I. & Ishizaki, T. (1995). Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4-hydroxylation recruited from an Indonesian population. British Journal of Clinical Pharmacology, 39, 297-303.
16. Shanks, G. D., Edstein, M. D., Chedester, A. L., Smith, C. D., Corcoran, K. D., Ngampochjana, M., Hansukjariya, P., Sattabongkot, J. & Webster, H. K. (1994). Proguanil plus sulfamethoxazole is not causally prophylactic in the Macaca mulatta-Plasmodium cynomolgi model. American Journal of Tropical Medicine and Hygiene, 50, 641-645.
17. Trager, W. & Jensen, J. B. (1976). Human malaria parasites in continuous culture. Science, 193, 673-675.
18. Ward, S. A., Watkins, W. M., Mberu, E., Saunders, J. E., Koech, D. K., Gilles, H. M., Howells, R. E. & Breckenridge, A. M. (1989). Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. British Journal of Clinical Pharmacology, 27, 781-787.
19. Ward, S. A., Helsby, N. A., Skjelbo, E., Brosen, K., Gram, L. F. & Breckenridge, A. M. (1991). The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. British Journal of Clinical Pharmacology, 31, 689-692.
20. Watkins, W. M., Mberu, E. K., Nevill, C. G., Ward, S. A., Breckenridge, A. M. & Koech, D. K. (1990). Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Transactions of the Royal Society of Tropical Medicine and Hygiene, 84, 492-495.
21. Wattanagoon, Y., Taylor, R. B., Moody, R. R., Ochekpe, N. A., Looareesuwan, S. & White, N. J. (1987). Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. British Journal of Clinical Pharmacology, 24, 775-780.